Evidence map›Paper›PMID 24291671›Full record

ArticleNeuroscience2014

Novel Vitamin K analogs suppress seizures in zebrafish and mouse models of epilepsy.

J J Rahn, J E Bestman, B J Josey, E S Inks, K D Stackley, C E Rogers, C J Chou, S S L Chan

Abstract read
In one paragraph

Article in Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

J J RahnDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
J E BestmanDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
B J JoseyDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
E S InksDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
K D StackleyDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
C E RogersDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
C J ChouDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: chouc@musc.edu.
S S L ChanDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: chans@musc.edu.
Medical University of South Carolina · US

Funding

SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2012 to 2020
$20.2M
TRAINING TO IMPROVE CARDIOVASCULAR THERAPIEST32HL007260 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MENICK, DONALD R. · 1985 to 2021
$11.1M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20RR024485 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2011 to 2011
$2.2M
Novel lysine deacetylase 6 Hsp domain inhibitors against AMLR01CA163452 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHOU, CHUNG-JEN JAMES · 2013 to 2017
$1.5M
The Mechanism of Mitochondrial DNA Proofreading in Human Health and DiseaseR00ES015555 · NIEHS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHAN, SHERINE S · 2009 to 2011
$747k
NCI NIH HHS 1R01CA163452NCI NIH HHS R01 CA163452NCRR NIH HHS 5P20RR024485-02NCRR NIH HHS P20 RR024485NCRR NIH HHS UL1 RR029882NCRR NIH HHS UL1RR029882NHLBI NIH HHS T32 HL007260NHLBI NIH HHS T32-HL007260-36NIEHS NIH HHS R00ES01555NIEHS NIH HHS R00 ES015555NIGMS NIH HHS 8 P20 GM103542-02NIGMS NIH HHS P20 GM103542
6 · The paper itself

Abstract

Epilepsy is a debilitating disease affecting 1-2% of the world's population. Despite this high prevalence, 30% of patients suffering from epilepsy are not successfully managed by current medication suggesting a critical need for new anti-epileptic drugs (AEDs). In an effort to discover new therapeutics for the management of epilepsy, we began our study by screening drugs that, like some currently used AEDs, inhibit histone deacetylases (HDACs) using a well-established larval zebrafish model. In this model, 7-day post fertilization (dpf) larvae are treated with the widely used seizure-inducing compound pentylenetetrazol (PTZ) which stimulates a rapid increase in swimming behavior previously determined to be a measurable manifestation of seizures. In our first screen, we tested a number of different HDAC inhibitors and found that one, 2-benzamido-1 4-naphthoquinone (NQN1), significantly decreased swim activity to levels equal to that of valproic acid, 2-n-propylpentanoic acid (VPA). We continued to screen structurally related compounds including Vitamin K3 (VK3) and a number of novel Vitamin K (VK) analogs. We found that VK3 was a robust inhibitor of the PTZ-induced swim activity, as were several of our novel compounds. Three of these compounds were subsequently tested on mouse seizure models at the National Institute of Neurological Disorders and Stroke (NINDS) Anticonvulsant Screening Program. Compound 2h reduced seizures particularly well in the minimal clonic seizure (6Hz) and corneal-kindled mouse models of epilepsy, with no observable toxicity. As VK3 affects mitochondrial function, we tested the effects of our compounds on mitochondrial respiration and ATP production in a mouse hippocampal cell line. We demonstrate that these compounds affect ATP metabolism and increase total cellular ATP. Our data indicate the potential utility of these and other VK analogs for the prevention of seizures and suggest the potential mechanism for this protection may lie in the ability of these compounds to affect energy production.

Indexed as

Adenosine TriphosphateAnimalsAnticonvulsantsCell LineDisease Models, AnimalDose-Response Relationship, DrugDrug InteractionsEnzyme InhibitorsEpilepsyMiceNaphthoquinonesOxygen ConsumptionPentylenetetrazoleProto-Oncogene Proteins c-fosSwimmingTime FactorsAdenosine TriphosphateAnticonvulsantsEnzyme InhibitorsNaphthoquinonesPentylenetetrazoleProto-Oncogene Proteins c-fosVitamin K 32-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid2-benzamido-1,4-naphthoquinone2h2j2-propylpentane hydroxamic acid2q3nadenosine triphosphateAEDanti-epileptic drugATPATP metabolismdays post fertilizationdimethyl sulfoxideDMEMDMSOdpfDulbecco’s Modified Eagle’s MediumECARelectron transport chainepilepsyETCextracellular acidification rateFCCPHDACHEPEShistone deacetylaseMBmethylene bluemitochondriaNational Institute of Neurological Disorders and StrokeNINDSNQN1OCRoxygen consumption ratepentylenetetrazolPTZreactive oxygen speciesrespirationROSSAHASEMSOD2standard error of the meansuberoylanilide hydroxamic acidsuperoxide dismutasetrifluorocarbonylcyanide phenylhydrazonevalproic acid, 2-n-propylpentanoic acidVitamin KVitamin K3VKVK3VK analog. It is a modification of analog 2j, with the addition of a terminal alkyne to the added benzeneVK analog. It is a modification of analog 2j with the addition of chlorine at the meta position of the added benzene ringVK analog. It was created by replacing the central methylene group of analog 2j with a carbonyl groupVK analog modified by the addition of a benzyl amine group to the 2′ position of the 1,4-naphthoquinone motif of VKVPAVPHAzebrafish

Identifiers

PMID24291671
PMCPMC3903788
OpenAlexW2033967885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.